Sandoz to Acquire CIMERLI from Coherus for $170 Million | Goodwin

On January 22, 2024, Sandoz announced its plans to acquire the U.S. biosimilar ranibizumab CIMERLI (ranibizumab-eqrn) from Coherus BioSciences, Inc. (“Coherus”) for an upfront cash...

Related Keywords

United States , ,Coherus Biosciences Inc ,Coherus Biosciences ,